NaQuinateAlternative Names: Osteopura
Latest Information Update: 13 Jul 2016
At a glance
- Originator Haoma Medica
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic bone diseases; Osteoporosis
Most Recent Events
- 13 Jul 2016 Preclinical trials in Osteoporosis in United Kingdom (PO)
- 13 Jul 2016 Preclinical trials in Metabolic bone diseases in United Kingdom (PO)